Beyond oncology--application of HPMA copolymers in non-cancerous diseases.
Macromolecular drug conjugates have been developed to improve the efficacy and safety profile of various therapeutic agents for many years. Among them, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates are the most extensively studied delivery platforms for the effective treatment of cancer. In recent years, the applications of HPMA copolymers for the treatment of a broader range of non-cancerous diseases have also been explored. This review highlights the recent developments in the rational design, synthesis, and evaluation of novel HPMA copolymer-drug conjugates for non-cancerous diseases, such as musculoskeletal diseases, infectious diseases and spinal cord injury. The translation potential of these applications is also briefly discussed.
Liu
Xin-Ming
XM
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA.
Miller
Scott C
SC
Wang
Dong
D
D000178:Acrylamides / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006801:Humans; D050997:Nanomedicine / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy; D010024:Osteoporosis / Q000188:drug therapy; D011108:Polymers / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use*
D000178:Acrylamides; D011108:Polymers; C032976:N-(2-hydroxypropyl)methacrylamide